Page 242«..1020..241242243244..250260..»

Clinical Epigenetics | Home page

Posted: August 14, 2022 at 2:17 am

Editors-in-Chief

Lucia Altucci,Universitdegli Studi della Campania, ItalyMarianne Rots,University Medical Center Groningen, Netherlands

Encompassing the broad spectrum of epigenetics research frombasicresearch to innovations in therapeutic treatments,Clinical Epigeneticsis a top tier, open access journal devoted to the study of epigenetic principles and mechanisms as applied to human development,disease, diagnosis and treatment. The journal particularly welcomes submissions involving clinical trials,translational research,new and innovative methodologies and model organisms providing mechanistic insights. The journal is divided into the following sections:

For more information on the section aims and scope visit our sectioninformation page. If you are unclear which section would be best suited to your submission, we invite you to submit a pre-submission inquiry by selecting the Contact Us option here.

Manuscripts focusing on differential RNA expression levels (coding or non-coding) or on RNA modifications cannot be considered for publication in Clinical Epigenetics since these aspects are not part of epigenetics per se.

In general, non-coding RNAs affect their target genes at the RNA level, which classifies these molecules as post-transcriptional gene expression regulators. The chromatin effects induced by some ncRNA do not yet justify this, to be included as a general mechanism of action of non-coding RNAs. Similarly, although modifications of RNA molecules resemble modifications of DNA or histone proteins, so do post-translational modifications of non-chromatin proteins. As such, RNA modifications are a novel class of markers, but they are not different from general posttranslational protein modifications (which also are not considered part of epigenetics).

For manuscripts on non-coding RNAs or RNA modifications to be considered for publication in Clinical Epigenetics, the authors must provide at least one of the following:

Manuscripts reporting on straightforward bioinformatic analyses of publicly accessible databases only, cannot be considered for publication in Clinical Epigenetics, unless the manuscript presents:

In October 2011, Clinical Epigenetics became a fully open access journal and is now published as part of BioMed Central's portfolio of journals. To view the journal's content prior to this transition, please see SpringerLink.

Continued here:
Clinical Epigenetics | Home page

Posted in Epigenetics | Comments Off on Clinical Epigenetics | Home page

Your True Age Might Not Be Your Birthdate And Thats Good News – Goalcast

Posted: August 14, 2022 at 2:17 am

You know the old expression: Youre only as old as you feel, right? Well, its wrong. Youre actually only as old as your epigenetic age, or, in other words, youre as old as the methylation of your DNA. Dont worry, well unpack the terminology in a moment, but first lets talk about thing in broader strokes.

In simpler terms, a better measurement than chronological age, which is literally the amount of time that you have been alive, is your biological age. That is to say biological age is the better metric when it comes to matters of health, predictions of longevity, and the potential for you to avoid various diseases and age-related conditions.

For a visual representation of biological age vs. chronological age and we make this comparison with nothing but respect, please note look at a picture of President Franklin D. Roosevelt in the last year of his life, then look at a picture of actor Vigo Mortensen. FDR died at 63, the age of Mortensen is at the time of this writing. Yes, the years on the books may be the same, but the aging process clearly weighed on those two quite differently.

How can peoples biological age be so different from one another even when chronological ages line up? While certain factors, such as congenital diseases, accidents, and exposures to harmful substances can cause issues for anyone, generally speaking, a healthy, active lifestyle will lead to a biological age that is younger than your birthday might suggest. Living well really will help you live a longer, better life.

As is usually the case in life, however, there is a flip side to this coin: many peoples biological age is actually notably older than their chronological age.

Epigenetic age acceleration is when your DNA has aged more rapidly than would be expected based on your chronological age. According to a study published by the JAMA Network, people who were found to have a lower epigenetic age were much more likely to reach age 90 with intact cognitive function and mobility, while those of more advanced biological age were more likely to be physically and cognitively impaired if they did reach that age, and also, of course, were much less likely to reach that advanced age.

It must be noted that this study was only focused on women, so while the results may apply to all genders universally, take the findings in their context or with a grain of salt.

Epigenetic age is calculated by looking at DNA methylation, which is a natural process wherein methyl groups bind to DNA. Some methylation is necessary is required for the proper function of DNA molecules, but if an abundance occurs, it can begin to restrict proper expression of the DNA. In people of advanced epigenetic age, more DNA methylation is presented.

You probably wont be shocked by the factors that lead to epigenetic age acceleration. According to Oxford Academics publication Environmental Epigenetics: DNA methylation can be influenced by environmental factors such as diet, hormones, stress, drugs, or exposure to environmental chemicals. In other words, an unhealthy lifestyle leads to less health right down to your very genes.

The choices you make in life, such as whether or not you smoke, regularly consume alcohol, take drugs, and eat heavily processed foods will take a toll on your DNA. So too can where you live, as pollution is terrible for health, as well as factors in your life like a high-stress job, poor sleep habits, and more.

There is a silver lining to be found for anyone who learns that their epigenetic age is older than their chronological age: unlike your actual age based on year and birthdate, your epigenetic age can be lowered again.

With a healthy diet and regular cardio exercise, ideally both of which are initially supported by a nutrition and fitness expert, you can effectively turn back the clock on genetic aging. In fact, according to a study shared by the National Library of Medicine, switching to a proper diet and committing to regular exercise can reduce genetic age by more than 3.2 years. And not only will eating well and getting exercise help you live longer and feel better later in life, but it will help you feel better now, as well.

Advances in medicine, better access to food and water, and, for many people around the world, safer, cleaner living conditions are already seeing a dramatic increase in life expectancy. Focusing in only on America for the sake of an apples-to-apples comparison, consider the average life expectancy for a person living in America in the middle of the 19th century.

The average life expectancy then was 40 years, per Statista. By the year 1900, life expectancy in America was still a bit under 50 years. In 1950, the average American could expect to live to 67. By the year 2000, it was 76, and today it is around 78 years. Were already living longer than ever, in terms of our chronological lives. And again, we have no control over how old we are based on the calendar, but we can take some measure of control over our genetic age.

So, what can you do, specifically, to ensure your biological age is as young as possible? For starters, you need to remove as many of those negative factors noted before (smoking, excessive alcohol, stress, and so forth) from your life as you can.

Certain diets, used intermittently, may be able to increase the efficiency of the mitochondria in your cells, and that can do wonders for reducing your biological age. Intermittent fasting, a ketogenic diet, and other approaches can be tried from time to time, though overall the best diet is one that is balanced.

Stress reduction techniques like mindful meditation or sensory deprivation can have lasting effects in your wellness, reducing cortisol levels in your body and helping increase your physical health along with your mental wellbeing.

And of course, exercise is a must. A study cited by Eat This Not That noted higher intensity exercise, engaged in multiple times per week, is the best way to turn back the clock on epigenetic aging. But any exercise is better than none, so even if you cant get to an Orange Theory class or a kickboxing lesson, a walk or jog around the neighborhood will still help.

More here:
Your True Age Might Not Be Your Birthdate And Thats Good News - Goalcast

Posted in Epigenetics | Comments Off on Your True Age Might Not Be Your Birthdate And Thats Good News – Goalcast

Efficacy of Neoadjuvant Immunotherapy on Breast Cancer is Independent of Race – Pharmacy Times

Posted: August 14, 2022 at 2:17 am

New study shows that race does not influence outcomes from immunotherapy for aggressive triple-negative breast cancer.

Black and non-Black patients who take durvalumab (Imfinzi) and chemotherapy before surgery have positive outcome for triple-negative breast cancer (TNBC), according to a phase 1/2 clinical trial published in Clinical Cancer Research.

Black patients continue to be underrepresented in investigational therapies and clinical trials, according to Lajos Pusztai, MD, DPhil, professor of medicine, and co-leader of the Genetics, Genomics, and Epigenetics Program;1 however, they are the ones most affected by TNBC.1,2

TNBC does not test positive for estrogen receptors, progesterone receptors, or the human epidermal growth factor receptor 2 (HER2) protein, which are indicators of other forms of breast cancer.2

TNBC makes up 10%-15% of all breast cancers, differing from other breast cancers because it grows and spreads faster, has less treatment options, and has a worse outcome.2 It also tends to afflict women younger than 40 years of age.2

The low accrual of ethnic minorities, particularly Black Americans, in clinical trials is problematic for several reasons, Pusztai said in a press release. For one, it means Black patients are not given equitable access to potentially lifesaving new treatments very early on. Secondly, it limits our ability to study potential differences in drug metabolism, toxicity, and efficacy between populations with different ancestries.1

The immunotherapeutic durvalumab targets the PD-1/PD-L1 immune checkpoint pathway. Other studies done by these study authors indicated that durvalumab benefited patients with non-metastatic TNBC when combined with chemotherapy and administered before surgery.1

This study was limited, however, because the participants were not an accurate reflection of the racial or ethnic makeup of the disease population in the surrounding neighborhood, according to the authors.1

Pusztai and colleagues decided to enter more patients into this original trial. This could help them understand the efficacy of durvalumab and chemotherapy (pre-surgery) on Black patients who make up the majority of TNBC patients.1

The trial incorporated 67 new patients21 people identified as Black,40 as non-Hispanic white patients, 3 as Hispanic/Latino, and 3 as Asian. The local community was better reflected with 31% of participants identifying as Black. Race did not differ across baseline tumor features.1

The pathologic complete response (pCR) to neoadjuvant durvalumab and chemotherapy was not significantly different with race. Of the 31 patients who had a positive pCR and no sign of cancer, 43% of patients were Black and 48% were non-Black patients.1

Rates of metastatic recurrence were also not significantly different between Black and non-Black patients, at 14% and 17%, respectively. Further, there were not significant differences observed in the 3-year overall survival (OS) Black and non-Black patients (81% and 87%, respectively) or 3-year event-free survival (71.4% and 78.3%, respectively).1

Patients with a pCR had significantly longer event-free survival and OS in Black and non-Black patients. With a pCR, the 3-year OS rate was 96.8% and the event-free survival rate was 90.3%, compared to 81.8% and 66.7% for those without a pCR, respectively.1 The study was limited by a small sample size and single institution location, according to the authors.1

Our study demonstrates that if patients are given similar treatment and similar follow-up, the differences in outcomes between Black and non-Black patients are reduced, Pusztai said. By improving health care access and delivery, we could mitigate some of the health care disparities that exist in our society.1

Reference

Benefits of pre-surgical immunotherapy were independent of race in patients with aggressive breast cancer. EurekAlert! July 29, 2022. Accessed on July 29, 2022. https://www.eurekalert.org/news-releases/960058

See the rest here:
Efficacy of Neoadjuvant Immunotherapy on Breast Cancer is Independent of Race - Pharmacy Times

Posted in Epigenetics | Comments Off on Efficacy of Neoadjuvant Immunotherapy on Breast Cancer is Independent of Race – Pharmacy Times

Getting a Stem Cell or Bone Marrow Transplant – American Cancer Society

Posted: August 14, 2022 at 2:10 am

When the decision is made to have a stem cell or bone marrow transplant, there are several steps in theprocess. The steps are much the same, no matter what type of transplant youre going to have.

You will first be evaluated to find out if you are eligible for a transplant. A transplant is very hard on your body. For many people, transplants can mean a cure, but for some people, problems can lead to severe complications or even death. Youll want to weigh the benefits and risks before you start.

Transplants can also be hard emotionally. They often require being in the hospital, being isolated, and theres a high risk of side effects. Many of the effects are short-term, but some problems can go on for years. This can mean changes in the way you live your life. For some people its just for a while, but for others, the changes may be lifelong. Some of the side effects are really unpleasant and can be serious. Your cancer care team will do everything they can to make you comfortable, but some of the side effects may not be completely controlled or relieved.

Before you have a transplant, you need to discuss the transplant process and all its effects with your doctors. It also helps to talk with others who have already had transplants.

Its also very hard going through weeks and months of not knowing how your transplant will turn out. This takes a lot of time and emotional energy from the patient, caregivers, and loved ones. Its very important to have the support of those close to you. For example, youll need a responsible adult who will be with you to give you medicines, help watch for problems, and stay in touch with your transplant team after you go home. Your transplant team will help you and your caregiver learn what you need to know. The team can also help you and your loved ones work through the ups and downs as you prepare for and go through the transplant.

Many different medical tests will be done, and questions will be asked to try to find out how well you can handle the transplant process. These might include:

You will also talk about your health insurance coverage and related costs that you might have to pay.

You may have a central venous catheter (CVC) put into a large vein in your chest. This is most often done as outpatient surgery, and usually only local anesthesia is needed (the place where the catheter goes in is made numb). Nurses will use the catheter to draw blood and give you medicines.

If youre getting an autologous transplant, a special catheter can be placed that can also be used when your stem cells are being removed or harvested.

The CVC will stay in during your treatment and for some time afterward, usually until your transplanted stem cells have engrafted and your blood counts are on a steady climb to normal.

Younger people, people who are in the early stages of disease, or those who have not already had a lot of treatment, often do better with transplants. Some transplant centers set age limits. Some people also may not be eligible for transplant if they have other major health problems, such as serious heart, lung, liver, or kidney disease. A mini-transplant, described under Allogeneic stem cell transplant in Types of Stem Cell Transplants for Cancer Treatment may be an option for some of these people.

The hospitals transplant team will decide if you need to be in the hospital to have your transplant, if it will be done in an outpatient center, or if you will be in the hospital just for parts of it. If you have to be in the hospital, you will probably go in the day before pre-transplant chemo or radiation treatment begins (see the next section), the transplant team makes sure you and your family understand the process and want to go forward with it.

If you will be having all or part of your transplant as an outpatient, youll need to be very near the transplant center during the early stages. Youll need a family member or loved one to be a caregiver who can stay with you all the time. You and the caregiver will also need reliable transportation to and from the clinic. The transplant team will be watching you closely for complications, so expect to be at the clinic every day for a few weeks. You may still need to be in the hospital if your situation changes or if you start having complications.

To reduce the chance of infection during treatment, patients who are in the hospital are put in private rooms that have special air filters. The room may also have a protective barrier to separate it from other rooms and hallways. Some have an air pressure system that makes sure no unclean outside air gets into the room. If youre going to be treated as an outpatient, you will get instructions on avoiding infection. Usually, people who have transplants are in a separate, special part of the hospital to keep as many germs away as possible.

The transplant experience can be overwhelming. Your transplant team will be there to help you prepare for the process physically and emotionally and to discuss your needs. Every effort will be made to answer questions so you and your family fully understand what will be happening to you as you go through transplant.

Its important for you and your family to know what to expect, because once conditioning treatment begins (see the next section), theres no going back there can be serious problems if treatment is stopped at any time during transplant.

Having a transplant takes a serious commitment from you and your caregiver and family, so it is important to know exactly what to expect.

Conditioning, also known as pre-transplant treatment,bone marrow preparation, or myeloablation, is usually treatment with high-dose chemo and/or radiation therapy. Its the first step in the transplant process and typically takes a week or two. Its done for one or more of these reasons:

The conditioning treatment is different for every transplant. Your treatment will be planned based on the type of cancer you have, the type of transplant, and any chemo or radiation therapy youve had in the past.

If chemo is part of your treatment plan, it will be given in your central venous catheter and/or as pills. If radiation therapy is planned, its given to the entire body (called total body irradiation or TBI). TBI may be given in a single treatment session or in divided doses over a few days.

This phase of the transplant can be very uncomfortable because very high treatment doses are used. Chemo and radiation side effects can make you sick, and it may take you months to fully recover. A very common problem is mouth sores that will need to be treated with strong pain medicines. You may also have nausea, vomiting, be unable to eat, lose your hair, and have lung or breathing problems.

Conditioning can also cause premature menopause in women and often makes people sterile (unable to have children). (See Stem Cell Transplant Side Effects.)

After the conditioning treatment, youll be given a couple of days to rest before getting the stem cells. They will be given through your central venous catheter, much like a blood transfusion. If the stem cells were frozen, you might get some drugs before the stem cells are given. These drugs are used to help reduce your risk of reacting to the preservatives that are used when freezing the cells.

If the stem cells were frozen, they are thawed in warm water then given right away. There may be more than 1 bag of stem cells. For allogeneic or syngeneic transplants, the donor cells may be harvested (removed) in an operating room, and then processed in the lab right away. Once they are ready, the cells are brought in and given to you theyre not frozen. The length of time it takes to get all the stem cells depends on how much fluid the stem cells are in.

You will be awake for this process, and it doesnt hurt. This is a big step and often has great meaning for patientsand their families. Many people consider this their rebirth or chance at a second life. They may celebrate this day as they would their actual birthday.

Side effects from the infusion are rare and usually mild. The preserving agent used when freezing the stem cells causes many of the side effects. For instance, you might have a strong taste of garlic or creamed corn in your mouth. Sucking on candy or sipping flavored drinks during and after the infusion can help with the taste. Your body will also smell like this. The smell may bother those around you, but you might not even notice it. The smell, along with the taste, may last for a few days, but slowly fades away. Often having cut up oranges in the room will offset the odor. Patients who have transplants from cells that were not frozen do not have this problem because the cells are not mixed with the preserving agent.

Other side effects you might have during and right after the stem cell infusion include:

Again, side effects are rare and usually mild. If they do happen, they are treated as needed. The stem cell infusion must always be completed.

The recovery stage begins after the stem cell infusion. During this time, you and your family wait for the cells to engraft, or take, after which they start to multiply and make new blood cells. The time it takes to start seeing a steady return to normal blood counts varies depending on the patient and the transplant type, but its usually about 2 to 6 weeks. Youll be in the hospital or visit the transplant center daily for a number of weeks.

During the first couple of weeks youll have low numbers of red and white blood cells and platelets. Right after transplant, when your counts are the lowest, you may be given antibiotics to help keep you from getting infections. You may get a combination of anti-bacterial, anti-fungal, and anti-viral drugs. These are usually given until your white blood cell count reaches a certain level. Still, you can have problems, such as infection from too few white blood cells (neutropenia), or bleeding from too few platelets (thrombocytopenia). Many patients have high fevers and need IV antibiotics to treat serious infections. Transfusions of red blood cells and platelets are often needed until the bone marrow starts working and new blood cells are being made by the infused stem cells.

Except for graft-versus-host disease, which only happens with allogeneic transplants, the side effects from autologous, allogeneic, and syngeneic stem cell transplants are much the same. Problems may include stomach, heart, lung, liver, or kidney problems. (Stem Cell Transplant Side Effects goes into the details.) You might also go through feelings of distress, anxiety, depression, joy, or anger. Adjusting emotionally after the stem cells can be hard because of the length of time you feel ill and isolated from others.

You might feel as if you are on an emotional roller coaster during this time. Support and encouragement from family, friends, and the transplant team are very important to get you through the challenges after transplant.

The discharge process actually begins weeks before your transplant. It starts with the transplant team teaching you and your primary (main) caregiver about:

For the most part, transplant centers dont send patients home until they meet the following criteria:

(Why Are Stem Cell Transplants Used as Cancer Treatment? has more information about neutrophils, platelets, and hematocrit).

If you do not meet all of these requirements, but still dont need the intensive care of the transplant unit, you might be moved to another oncology unit. When you do go home, you might need to stay near the transplant center for some time, depending on your condition.

The process of stem cell transplant doesnt end when you go home. Youll feel tired, and some people have physical or mental health problems in the rehabilitation period. You might still be taking a lot of medicines. These ongoing needs must now be managed at home, so caregiver and friend/family support is very important.

Transplant patients are followed closely during rehab. You might need daily or weekly exams along with things like blood tests, and maybe other tests, too. During early rehab, you also might need blood and platelet transfusions, antibiotics, or other treatments. At first youll need to see your transplant team often, maybe even every day, but youll progress to less frequent visits if things are going well. It can take 6 to 12 months, or even longer, for blood counts to get close to normal and your immune system to work well. During this time, your team will still be closely watching you.

Some problems might show up as much as a year or more after the stem cells were infused. They can include:

Other problems can also come up, such as:

Your transplant team is still there to help you, even though the transplant happened months ago. Its important that you tell them about any problems you are having they can help you get the support you need to manage the changes that you are going through. They can also help you know if problems are serious, or a normal part of recovery. The National Bone Marrow Transplant Link helps patients, caregivers, and families by providing information and support services before, during, and after transplant. They can be reached at 1-800-LINK-BMT (1-800-546-5268) or online at http://www.nbmtlink.org.

Read more:
Getting a Stem Cell or Bone Marrow Transplant - American Cancer Society

Posted in Stem Cell Treatments | Comments Off on Getting a Stem Cell or Bone Marrow Transplant – American Cancer Society

Stem cell therapy to be used in treatment of long COVID by Panacell Biotech – Labiotech.eu

Posted: August 14, 2022 at 2:10 am

A South Korean biotech company says it will use natural killer (NK) cells, exosomes and brown adipose-derived stem cells (ADSC) as treatment of long COVID.

NK cells are a type of immune cell that have granules or small particles that can kill tumor cells or those infected with a virus. Panacell Biotech said they can be used to treat those with terminal illness as well as those with long COVID or post COVID-19 conditions.

The company isSouth Koreasresearch institute specializing in advanced regenerative medical cell therapy using adipose-derived stem cells (ADSC).

It announced today (August10)that it will soon conduct those cells toxicity tests through clinical trials and laboratory animals.

Currently, inSouth Korea, there are guidelines for plasma treatment that administers plasma from patients who have recovered from COVID-19 to other patients. Although there already exist COVID-19 treatments, such as Paxlovid,aclear therapeutic effect has not been confirmed yet.

There are more than 60 long COVID conditions.

According to the Mayo Clinic, one in four people aged 65 or above suffer from aftereffects of COVID-19.

It has been reported that people with long COVID often experience an extremely broad variety of symptoms, including less well-known side effects such as amnesia, and an inability to perform familiar movements or commands.

Panacell said it is believed that about four million people or 2.4% of the U.S. employed population have reduced ability to work because of long COVID.

Associate professor Gwenalle Douaud at the Nuffield Department of Clinical Neurosciences (NDCN),University of Oxford, said her team observed a greater reduction in grey matter thickness and tissue contract in the orbitofrontal cortex and parahippocampal gyrus.

She said: We saw greater changes in markers of tissue damage in regions that are functionally connected to primary olfactory cortex.

While the long-term effects of COVID-19 on smell remaininconclusive, the study suggests a possible connection between brain changes by COVID-19 and memory.

The company says there have been many clinical results in which the coronavirus causes inflammation in various organs, including the respiratory system, and chronic symptoms persist.

Sun Yanrong, deputy director of the China Biotechnology Development Center, said: We are continuing to monitor the treatment using stem cells. InWuhan, over 200 patients have already been treated with stem cells.

The clinical treatment results show that the stem cell therapy has good safety and has also been confirmed to have a therapeutic effect. It was also effective in recovering the lungs.

Seung-Ho Choi, CEO of Panacell Biotech, added: We expect that this clinical trial will reveal therapeutic effects of stem cell therapy along with these treatments.

Panacell Biotech is a bio institute in advanced regenerative medicine and cell therapy, recognized for its contributions to the development of biotechnology by researching stem cell culture and cell banking, focusing on the development of treatments for various cancers and incurable diseases.

Excerpt from:
Stem cell therapy to be used in treatment of long COVID by Panacell Biotech - Labiotech.eu

Posted in Stem Cell Treatments | Comments Off on Stem cell therapy to be used in treatment of long COVID by Panacell Biotech – Labiotech.eu

Selma Blair ‘Stopped Looking in the Mirror’ After MS Treatments – TooFab

Posted: August 14, 2022 at 2:10 am

Selma Blair reveals how she's changed her approach to beauty and makeup since her 2018 multiple sclerosis diagnosis.

During an interview with InStyle, the 50-year-old actress got candid about her new approach to life and how her chronic disease had inspired her to create a beauty brand after undergoing her medical treatments.

"After I had treatment, I'd honestly, like, stopped looking in the mirror," Blair confessed. "My hair was short, I was bloated, I had alopecia on my lashes and my face. And it was all so much effort I sometimes don't see well so I just stopped, and I didn't think I missed it."

Although the side effects may have kept her from looking in the mirror, the "Legally Blonde" star insists that she never viewed makeup or self-care as "frivolous."

Selma Blair Opens Up About Alleged Assault by Now Ex-Boyfriend That Landed Her in Hospital View Story

Rather, she revealed that beauty, fashion and makeup had always been powerful tools in her self-care kit. Developing products for her brand Guide Beauty that were still accessible to use after the effects of her MS diagnosis became "a real turning point."

"I've never thought of fashion, makeup really, any of our ways of self-care and presenting ourselves as frivolous," she said "It was a real turning point for me, it was like, 'OK, let's start waking up again.'"

Guide Beauty features a collection of makeup and beauty tools that "invite everybody to the table" and are easy to use for people who suffer from MS, chronic diseases or have other disabilities.

"You're not designing for an 'us' or a 'them,'" she explained. "You're just looking to design for that beautiful 'we' moment: When we all get to play in the same world together with makeup."

Back in August 2021, Blair gave an update on her battle with MS during her virtual appearance at Discovery+'s TCA presentation. At the time she revealed that she was "in remission" after she had a stem cell transplant and underwent chemotherapy.

Selma Blair 'Told to Make Plans for Dying' in Incredibly Moving Documentary Trailer View Story

"My prognosis is great. I'm in remission. Stem cell put me in remission," the actress said per PEOPLE. "It took about a year after stem cell [transplant] for the inflammation and lesions to really go down."

"I was reluctant to talk about it because I felt this need to be more healed and more fixed," she added. "I've accrued a lifetime of some baggage in the brain that still needs a little sorting out or accepting. That took me a minute to get to that acceptance. It doesn't look like this for everyone."

"I have really felt unwell and misunderstood for so long that it's just, me," Blair said.

"The Sweetest Thing" actress added that being diagnosed with MS "can be very isolating," but said she was fortunate to have a strong support system.

"People took great care of me. I never really like life. I do now -- strange, huh?" she said. "Just because life's so weird. I was so scared in life. To suddenly start to find an identity and a safety in me, to figure out boundaries, time management and energy. I'm having the time of my life."

Excerpt from:
Selma Blair 'Stopped Looking in the Mirror' After MS Treatments - TooFab

Posted in Stem Cell Treatments | Comments Off on Selma Blair ‘Stopped Looking in the Mirror’ After MS Treatments – TooFab

Multiphoton Microscopy Market Insights, New Innovations, Research and Growth Factor till 2031 – BioSpace

Posted: August 14, 2022 at 2:08 am

Wilmington, Delaware, United States, Transparency Market Research Inc. Advances in optical technologies continue to enrich biomedical research. The drive for multiphoton microscopy (MPM) market stems from the ever-growing demand for better tools for real-time observation of cells, both for clinical and research applications. multiphoton microscopy (MPM) is gaining traction as an advanced optical imaging technique for imaging of living, intact biological tissues, notably from the tissue to sub-cellular scale.

The evolution of the multiphoton microscopy market pivots on the strides made in the biological sciences increasingly in relation to adoption of new tools for disease diagnosis, notably in gastrointestinal diseases. The focus of healthcare facilities to increase access of advanced tools for endoscopists which expand the armamentarium of tools available for histopathological diagnosis of abnormal lesions. Thus, new technologies in the multiphoton microscopy market are moving ahead across the path of commercialization in the multiphoton microscopy market.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=83283

Multiphoton Microscopy Market: Drivers, Current Prospects, Lucrative Avenues

Researchers are likely to harness the current array of MPM technologies for understanding complex biological interactions, furthering understanding pathophysiological processes underlying various diseases for human and other living animals. The demand for MPM has thus grown steadily to meet the various applications notably in in-vivo and ex vivo settings. Enormous research on cell migration, metastasis, and tumor progression using multiphoton microscopy is opening gates to opportunities for players in the multiphoton microscopy market.

Advancements in fiber optics together with the trend of miniaturization of electronics used for biomedical sciences is a key factor propelling prospects of the multiphoton microscopy market. One of the key advantages of MPM emanates from it being a non-invasive imaging system, which makes it especially suitable for observe complex tumor microinvasion without causing any significant damage to the living cells. More such advantages are propelling the attractiveness of products in the multiphoton microscopy market. The less toxicity makes multiphoton microscopy preferable for tumor-stroma interactions, for instance.

Request for TOC - https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=83283

Multiphoton Microscopy Market: Competition Landscape

Several providers of imaging technologies and solutions in the multiphoton microscopy market are keenly looking to expand the features for achieving higher sensitivity and resolution of devices when used for deep imaging. Thus, players are expected to unlock revenue gains by targeting the customer proposition of high- sensitivity and -resolution imaging systems for dynamic cellular processes.

Many players in the market are tapping into new revenue streams in oncology research, such for study of tumor development and metastasis in animals. A few manufacturers have incorporate features that will make MPM suitable for understanding dermal physiology and pathology. A case in point is the promising use of such imaging systems for visualizing noncentrosymmetric molecules.

Some of the key players in the multiphoton microscopy market are Sutter Instrument, Femtonics, LaVision BioTec, Olympus Corporation, Carl Zeiss, Nikon, and Bruker.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=83283

Multiphoton Microscopy Market: Regional Landscape

North America and Europe have been lucrative multiphoton microscopy markets. The demand has thrived on the early adoption of cutting-edge imaging technologies for biomedical diagnostics and therapeutic applications. The U.S. is a highly attractive market for global players to consolidate their shares. Rise in R&D in stem cells has made businesses in the multiphoton microscopy market set their sights on the emerging market of Asia Pacific. The prevalence of some skin cancers and the increasing incidence of melanoma and non-melanoma in the region are key factors propelling market prospects of MPM.

Rise in geriatric population is increasing risks of non-melanoma skin cancer in the target population in Asia and Europe, thereby rendering these regional markets potentially profitable for lab equipment suppliers in the global market in the near future. Some of the key countries contributing lucrative avenues in the Asia Pacific multiphoton microscopy market are China, Japan, India, Australia, and South Korea.

More Trending Reports by Transparency Market Research

Medical Imaging Equipment Services Market: The global medical imaging equipment services market is anticipated to reach US$ 29.2 Bn by the end of 2031.

Ultra-large Volume Wearable Injectors Market: The global ultra-large volume wearable injectors market is anticipated to exceed US$ 6.6 Bn by the end of 2031.

Ambulance Services Market: The global ambulance services market is anticipated to reach more than US$ 70 Bn by the end of 2031. The global market is projected to register a CAGR of 4.5% from 2022 to 2031.

Depth of Anesthesia Monitoring Devices Market: The global depth of anesthesia monitoring devices market is anticipated to reach US$ 382.4 Mn by the end of 2031.

mHealth Services Market: The global mHealth services market is anticipated to reach US$ 415.6 Bn by the end of 2031. The global market is estimated to grow at a CAGR of 15.7% from 2022 to 2031.

Healthcare ERP Market: The global healthcare ERP market is expected to reach the value at US$ 9.6 Bn by the end of 2031. It is estimated to expand at a CAGR of 6.5% from 2021 to 2031.

Diabetes Supplements Market: The global diabetes supplements market is expected to reach the value of US$ 13.4 Bn by the end of 2031.

Population Health Management Solutions Market: The U.S. population health management solutions market is expected to reach the value of US$ 34.59 Bn by the end of 2028.

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

Follow this link:
Multiphoton Microscopy Market Insights, New Innovations, Research and Growth Factor till 2031 - BioSpace

Posted in Delaware Stem Cells | Comments Off on Multiphoton Microscopy Market Insights, New Innovations, Research and Growth Factor till 2031 – BioSpace

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Trends, Competitive Landscape and Regional Insights to 2031 – BioSpace

Posted: August 14, 2022 at 2:08 am

Wilmington, Delaware, United States, Transparency Market Research Inc. Stem cell technology is considered a highly developing one, that has a major role to play in regenerative medicine. It includes various other processes such as cellular therapies, developmental cell biology, gene therapy, tissue engineering, nanotechnology, chemical biology, and others.

Read Report Overview - https://www.transparencymarketresearch.com/autologous-stem-cell-non-stem-cell-therapies-market.html

Stem cells are capable of replacing the tissues and cells so as to heal various medical conditions such as arthritis, injury of the spinal cord, Parkinsons disease, and others. The rising adoption of stem cell technology for treating various diseases are likely to augment the growth of the global autologous stem cell and non-stem cell based therapies market during the forecast period set between 2021 and 2031.

Autologous stem cell and non-stem cell utilizes the cells with healthy blood stem from an individuals own body to replace the wounded or diseased bone marrow in terms of non-stem cell therapy. This therapy is considered one of the most platelet-rich plasma treatments wherein high concentration of growth factors with the ability to heal chronic wounds will be infused into the body as part of the therapy and will help cure chronic wounds. Thus, the market for autologous stem cell and non-cell based therapies is projected to rise significantly in the coming years.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4001

The report on the global autologous stem cell and non-stem cell based therapies market provides a comprehensive analysis of the market and factors supporting its growth. This includes factors that are boosting, repelling, challenging or creating new opportunities for this market.

The report also highlights the impact of the novel COVID19 pandemic on this market and how can players attract notable revenues during this time period by adopting strategies such as product innovations, product quality improvement, and others. The table of segmentation with emphasis on the leading segment and factors attributing to its growth are discussed in details in this report. For more information on the report, log on to the company website.

Request for ToC - https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=4001

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Competitive Landscape

The nature of the global autologous stem cell and non-stem cell based therapies market is fairly competitive with the presence of few players. While each player chalks out their own strategy of making a mark in the competitive landscape, the key objective is to increase the sales rate of irradiation apparatuses across all geographies. Some players invest on research and development activities to ensure their position amongst the top competitors of the market.

Some of the key players of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market include:

Ask for References - https://www.transparencymarketresearch.com/sample/sample.php?flag=ARF&rep_id=4001

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Growth Drivers

The advent and increasing adoption of latest technologies in the field of regenerative medicine sector is a prime factor promoting the growth of the global autologous stem cell and non-stem cell based therapies market.

Besides this, autologous stem cell and non-stem cell based therapies do not use any cell from foreign organism and thus, the possibility of the body rejecting its own cells is particularly less. This also means that the risk of immune reactions at the time of transplant surgery is far less with the help of such therapies. This will also help promote the growth of this market in the coming years. Furthermore, the increasing cases of cancer will also help promote the growth of this market in the coming years.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=4001

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Geographical Insights

Demographically, North America dominated the global autologous stem cell and non-stem cell based therapies market, followed closely by Europe. The ability to diagnose a large number of infectious disease and the fact that the complexity of a donor and a receiver is removed, it becomes less infectious and this factor will help increase the adoption of autologous stem cell and non-cell based therapies in well-established medical centers in the North American market continue to generate notable revenues in the forecast period as well.

More Trending Reports by Transparency Market Research

Neurotrophic Keratitis Market: The global neurotrophic keratitis market is projected to attain a market value of US$ 324 Mn by the end of 2027.

E. Coli Testing Market: The global E.coli testing market was valued at US$ 1380.0 Mn in 2018 and is anticipated to expand at a CAGR of 7.5% from 2019 to 2027.

Cardiac Pacemakers Market: The global cardiac Pacemakers market was valued at US$ 9,514.0 Mn in 2018 and is anticipated to expand at a CAGR of 7.8% from 2019 to 2027.

Hospital Acquired Disease Testing Market: The global hospital acquired disease testing market was valued at US$ 798.6 Mn in 2018 and is anticipated to expand at a CAGR of 14.7% from 2019 to 2027.

Single-use Bioprocessing Systems Market: The global single-use bioprocessing systems market is likely to be driven by the increasing expiry of patents of blockbuster molecules and rising demand for biologics.

Diagnostic Specialty Antibodies Market: The global diagnostic specialty antibody market was valued at US$ 22.6 Bn in 2018 and is anticipated to expand at a CAGR of 5.3% from 2019 to 2027.

Biotherapeutics Cell Line Development Market: The global biotherapeutics cell line development market is expected to reach ~US$ 224 Mn by 2030.

Genome Engineering Market: The global genome engineering market was valued at US$ 3,685.4 Mn in 2018 and is anticipated to expand at a CAGR of 10.9% from 2019 to 2027.

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

Read the rest here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Trends, Competitive Landscape and Regional Insights to 2031 - BioSpace

Posted in Delaware Stem Cells | Comments Off on Autologous Stem Cell and Non-Stem Cell Based Therapies Market Trends, Competitive Landscape and Regional Insights to 2031 – BioSpace

Reebok’s Nano X2 Adventure Helps You Take Your Workouts Anywhere – Gear Patrol

Posted: August 14, 2022 at 2:07 am

Now and again, it can be beneficial to mix up your workout environment. Whether swapping your garage gym workouts for driveway sweat sessions, hitting the trails over hitting the treadmill or just adding a few outdoor medicine ball tosses, getting fit outside can make for interesting yet motivating training.

To keep the pace and make the most of these wilder workouts, you need gear that's up for the trek. Outdoor training, depending on how adventurous you get, can mean aggressive surfaces, potential obstacles or debris, and worst of all, no comfortable air conditioning.

Reebok, the performance brand who knows a thing or two about indoor training, has seemingly answered these outdoor calls with the latest Nano iteration the Nano X2 Adventure. With added durability and protection from the elements, these vibrant, functional kicks can offer plenty of support to meet the needs of varying terrains and training demands.

"As the Nano franchise evolves, we continue to focus on versatility and style while keeping performance benefits at Nano's core," says Reebok Design Group Senior Product Manager Tal Short. "Whether you're taking on a driveway workout, or on a weekend hike, the Nano X2 Adventure is built to support athletes wherever their workouts take them."

Debuting in 2021 with the Nano X1 Adventure, this latest Nano X2 model continues the outdoor-inspired lineup with key upgrades built to withstand the rigors of outdoor training. A nylon ripstop upper boosts protection and durability against the elements while still retaining breathable comfort. A redesigned, more rugged outsole provides plenty of grip and traction to maximize every adventurous step as well. Lastly, screen prints and reflective style notes serve as a nod to the outdoors, taking inspiration from the natural wonders you'd see when out in the wild.

Of course, not all the elements are new and improved. After all, the Nano X2 already provides plenty of performance-ready qualities, like the Floatride Energy Foam midsole, which brings its energetic, responsive feel to this latest outdoor silhouette. A more defined heel clip is also carried over for optimal support and stability during heavy lifts and weighted exercises.

Unfortunately, your bold exploration of newfound training terrains will have to wait for a few weeks, at least, as the Nano X2 Adventure will be available on August 24 for $140 just $5 more than the typical Nano X2 cost. If you can't wait to embark on outdoor training, there is hope, however. Reebok UNLOCKED members will be granted early access to this adventurous new trainer beginning Thursday, August 18.

We're anxious to pursue this inspired outdoor training trend. Stay tuned for more coverage as we map out just how adventurous these new Nanos prove to be.

LEARN MORE

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

Visit link:
Reebok's Nano X2 Adventure Helps You Take Your Workouts Anywhere - Gear Patrol

Posted in Nano medicine | Comments Off on Reebok’s Nano X2 Adventure Helps You Take Your Workouts Anywhere – Gear Patrol

How Houston’s nonprofit funds early research that leads to breakthroughs like the COVID vaccine – Houston Chronicle

Posted: August 14, 2022 at 2:07 am

Jason McLellan was confident he was on his way to creating the first vaccine for human metapneumovirus, a respiratory disease that is common among children and the elderly, and could be dangerous to those with weakened immune systems. One small problem: He had some data, but likely not enough to grab the attention of federal funders like the National Institutes of Health.

This phenomenon is a Catch 22 researchers are all too familiar with -- Its difficult to get funding without data, but working unfunded makes it difficult to collect data.

Enter the Welch Foundation. In 2019, McLellan, while at the University of Texas, received $80,000 per year for three years from the Houston charity to fund his research. That funding went to research by McClellan and his colleagues that proved a vaccine technology used in the rapid development of COVID-19 vaccines.

For close to 70 years, the Welch Foundation has taken chances on scientists like McLellan, funding research at its earliest stages based on one major criterion: its a good idea. Since its founding in 1954, the foundation has provided some $1.1 billion in seed money for basic research that has led to breakthroughs in medicine, vaccines, and materials.

On HoustonChronicle.com: Houston could be a biotech hub, but its missing a key ingredient

But whether the research ever results in a commercial product has no bearing on the projects that the Welch Foundation funds, said Adam Kuspa, the charitys president. The only goal is to allow scientists in chemistry and related fields to pursue their own interests, with no expectations of where it might lead.

Its funding to allow basic science researchers in chemistry and related fields to follow their curiosity, Kuspa said, with no thought that there has to be a product in the end.

McLellans case, however, shows the many directions in which basic research can lead. In addition to its contribution to COVID vaccines, the research yielded a metapneumovirus vaccine that has been licensed by a pharmaceutical company and will enter clinical trials later this year. Human metapneumovirus affects more than 11 million people a year, according to a 2018 study.

Ultimately, taking on earlier stage research often means as many failures as successes, Kuspa said. But even failures advance knowledge perhaps more so than success and the successes, as McLellans vaccine work shows, can change the world for the good.

His story is an object lesson in why you fund basic research, Kuspa said.

The Welch Foundation was created when federal funding for research was a novel idea. One of the first major pushes by the federal government to fund the sciences came in 1940s, with efforts such as MITs Radiation Laboratory or Rad Lab, which was a private-public partnership that resulted in the creation of various radar systems used in World War II. It ultimately inspired the creation of the National Science Foundation, a government agency that supports fundamental research and education in science and engineering, in 1950. This showed the possibilities of funding research.

The foundation was created by the estate of Robert Welch in the 1950s. Welch came to Houston from South Carolina when he was 14 years old with almost no money in his pocket. He was quickly able to find a job at a local drugstore in Houston and then eventually worked as a bookkeeper and salesman, for the Bute Company, a paint firm.

It was the late 1800s, not long before the Spindletop gusher launched the first Texas oil boom. He would listen to businessmen come into the shop and talk about the oil and gas industry, and soon began buying and selling land and mineral rights for oil and gas development, earning his fortune.

He wanted to use his wealth to do good, and first considered a foundation to fund cancer research. But already coming out were the first chemotherapies, which he thought might cure cancer in a decade or two. Its unclear why Welch left his fortune to advance chemical research, but before he died in 1952, he created a trust of $25 million now valued at about $1 billion to support the foundation, which was formed in 1954.

The foundation usually has 300 grants going at a time, and provides researchers up to $100,000 a year for three years. This funding allows chemists to hire researchers, maintain their labs, buy chemical supplies, travel and cover any other expenses, Kuspa said.

In 2001, the Welch Foundation funded James Tour, a chemistry professor at Rice University, who was experimenting with nanotechnology, which manipulates materials at the molecular level to make functioning machines. He was developing nano cars, devices with four wheels an axles, but so tiny that 50,000 of them could be parked across the diameter of a human hair.

It was purely intellectual curiosity, Tour said. We didnt know what they would end up being good for.

But that curiosity ended up paying off. Throughout the 2000s Tour continued his research. He adapted the technology he created to build his nano cars to create nano machines that drill into cancerous cells and super bacteria bacteria becoming resistant to antibiotics. Welch Foundation funded research for the technology in 2019.

The nano machines proved successful in animal trials. Tour is now applying to the FDA to begin clinical trials.

On HoustonChronicle.com: MD Anderson launches joint venture with biopharma manufacturer, creating a potential launching pad for Houstons biotech ambitions

Often times, the foundation is among the first to back research projects. Livia Schiavinato Eberlin, an associate professor at Baylor College of Medicine, is developing a handheld device called the MasSpec Pen to tell surgeons whether issue has cancerous cells while they operate.

Doctors can easily tell where cancerous cells are concentrated, but, closer to the margins of tissue, it's difficult to determine where to stop cutting, Eberlin said. They dont want to risk leaving cancerous cells in the patient, but they also want to preserve as much normal tissue as possible.

Welch funded the research for the chemistry that makes the device work. The pen uses solvents to chemically extract molecule samples from living tissue. Once she had research understanding how the device could work, she was able to get funding to create prototype from the National Institutes of Health and then The Cancer Prevention and Research Institute of Texas, a state agency that funds cancer research. Additional funders came on recently.

The device is in pilot studies, which precede FDA clinical trials. It has been tested by more than 20 surgeons at MD Anderson Cancer Center and Baylor College of Medicine, and Eberlin estimates it could win FDA approval within 5 years.

Having a continuous source of stable funding makes a huge difference, Eberlin said, especially for early career investigators like me.

Basic research is a matter of economic and international security, said Yousif Shamoo, former vice provost for Research at Rice University.

Historically, the United States has led the world in investing in research and development, but other countries are challenging that lead. U.S. investment in research and development, as a percentage of the economic output, has remained stagnant for nearly half a century, while China has increased research funding at about 2 percent a year, relative to its economy, according to a 2020 report from Rice Universitys Baker Institute and the American Academy of Arts & Sciences.

China is on track to surpass the United States in total research and development spending by 2030, according to a 2020 report from the National Science Board.

Investing in basic research is how the great nations become great, Shamoo said. They have this ability to see into the future by investing in things that 20 or 30 years from now produce big wins and really disruptive technologies that change everybody's lives.

Early funding also can help disruptive technologies come to fruition faster. Eberlins MasSpec Pen was just an idea in 2016, but is now undergoing multiple trials supersonic speed for academia, she said. Without early funding from the Welch foundation, she doesnt think her device would be so far along.

Without would have been a lot more difficult time consuming, stressful, Eberlin said, and we probably would have wouldn't have accomplished what we did in just a few years.

becca.carballo@chron.com

Go here to see the original:
How Houston's nonprofit funds early research that leads to breakthroughs like the COVID vaccine - Houston Chronicle

Posted in Nano medicine | Comments Off on How Houston’s nonprofit funds early research that leads to breakthroughs like the COVID vaccine – Houston Chronicle

Page 242«..1020..241242243244..250260..»